Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

See on Scoop.it - Medical-IT

In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic
acid for time to skeletal-related events. The results from this study suggest denosumab
could be an additional option for the standard of care for patients with multiple
myeloma with bone disease.

from Tumblr http://ift.tt/2DrUm1r
via IFTTT